You just read:

eFFECTOR Therapeutics' Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma

News provided by

eFFECTOR Therapeutics

09 Mar, 2017, 08:00 ET